– USA, MA – Gemini Therapeutics, a clinical-stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration and linked ocular disorders, today announced the appointment of David Lubner to its Board as an independent member.
“David is an accomplished finance executive, with more than 20 years of wide-ranging experience in the industry that complements and helps strengthen our team,” said Jason Meyenburg, CEO. “His expertise will be invaluable as our company evolves and we continue to advance our pipeline in dry AMD and linked diseases for patients with limited therapeutic options.”
“We’re thrilled to have David join our Board,” said Stephen Squinto, Ph.D., Board Chairman. “I’m confident the team will benefit from his strategic insights as Gemini continues to execute toward its goal of developing and delivering first-in-class precision therapeutics.”
About David Lubner
Mr. Lubner has served as Executive Vice President and Chief Financial Officer of Ra Pharma, which was acquired by UCB in April 2020. Before joining Ra Pharma, Mr. Lubner served as a member of the senior management teams of Tetraphase Pharmaceuticals, Inc., PharMetrics Inc., and ProScript. He also currently serves on the Board of Directors for Dyne Therapeutics and previously served on the board of directors for Nightstar Therapeutics until its acquisition by Biogen in 2019.
“I’m excited by Gemini’s efforts to bring a precision medicine approach into new disease areas like dry AMD, where they haven’t existed before,” said Mr. Lubner. “I look forward to supporting this talented team and Gemini’s continued growth as it works to translate a deep understanding of disease into innovative and targeted therapies for common but poorly understood ocular disorders.”
Mr. Lubner received his B.S. in Business Administration from Northeastern University and an M.S. in Taxation from Bentley University. He is a member of the American Institute of CPAs and is a Certified Public Accountant in the Commonwealth of Massachusetts.
About Gemini Therapeutics
Gemini Therapeutics is a clinical-stage precision medicine company developing innovative treatments for age-related macular degeneration and linked ocular disorders that are matched to specific genetic mutations found in patients with high clinical unmet need. Gemini’s lead clinical-stage candidate, GEM103, is a recombinant form of the naturally occurring complement factor H protein currently in a Phase 1 trial. The company has generated a rich pipeline including recombinant proteins, monoclonal antibodies, and gene therapies. Gemini’s CLARITY natural history study is designed to provide unprecedented insight into the role of genetic risk in common retinal diseases and began in December 2018. Gemini was launched with funding from leading life science investors and powered by academic partnerships globally.
For more information: https://geminitherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
